(Q53781705)

English

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate n

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate n (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

0 references

1 reference

based on heuristic

inferred from title

Monique C Minnema

14

object named as

Monique C Minnema

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

author name string

Lieke H van der Helm

1

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

Canan Alhan

2

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

Pierre W Wijermans

3

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

Marinus van Marwijk Kooy

4

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

Ron Schaafsma

5

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

Bart J Biemond

6

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

Aart Beeker

7

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

Mels Hoogendoorn

8

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

Bastiaan P van Rees

9

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

Okke de Weerdt

10

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

Jurgen Wegman

11

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

Ward J Libourel

12

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

Sylvia A Luykx-de Bakker

13

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

Rolf E Brouwer

15

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

Fransien Croon-de Boer

16

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

Matthijs Eefting

17

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

Kon-Siong G Jie

18

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

Arjan A van de Loosdrecht

19

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

Jan Koedam

20

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

Nic J G M Veeger

21

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

Edo Vellenga

22

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

Gerwin Huls

23

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

language of work or name

0 references

publication date

8 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

155

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

5

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

599-606

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

Proposals for the classification of the myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08893.X

21 January 2018

The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08893.X

21 January 2018

Nomenclature evolution: Changes in the ISCN from the 2005 to the 2009 edition

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08893.X

21 January 2018

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08893.X

21 January 2018

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08893.X

21 January 2018

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08893.X

21 January 2018

Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08893.X

21 January 2018

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08893.X

21 January 2018

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08893.X

21 January 2018

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08893.X

21 January 2018

Identifiers

10.1111/J.1365-2141.2011.08893.X

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21981697

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53781705&oldid=1545701478"